FDA Approves At-Home Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorders
Key Clinical Summary:
- The US Food and Drug Administration (FDA) approved dexmedetomidine (IGALMI) sublingual film for at-home treatment of agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults, according to Teva Pharmaceuticals.
- The phase 3 randomized, double-blind, placebo-controlled SERENITY At-Home Safety and Tolerability Trial included 102 patients, with 1160 agitation episodes treated over 12 weeks.
- No patients discontinued treatment because of tolerability, and the most common adverse events included somnolence, dry mouth, dizziness, oral paresthesia, and oral hypoesthesia.
The US Food and Drug Administration (FDA) has approved dexmedetomidine (IGALMI) sublingual film for at-home use for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults, announced manufacturer Teva Pharmaceuticals on November 16, 2026. According to the company, the approval marks the first at-home treatment option for agitation associated with these illnesses.
SERENITY At-Home Trial Evaluates Dexmedetomidine Safety and Tolerability
Between 25% and 40% of patients may experience agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders, with 21% of cases of acute agitation resulting in emergency department visits or hospitalizations, according to data cited by the company.
The approval is supported by findings from the phase 3 SERENITY At-Home Safety and Tolerability Trial. In the randomized, double-blind, placebo-controlled study of self-administered dexmedetomidine outside a health care setting, 1160 agitation episodes in 102 patients were treated over a 12-week study period.
There were no discontinuations due to tolerability, and the most common adverse events included somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia.
Dexmedetomidine Regulatory Context and Earlier Phase 3 Results
A supplemental new drug application (sNDA) sought to expand the existing approval of dexmedetomidine under health care provider supervision to include at-home use. The original approval was supported by data from the phase 3 SERENITY I and II trials. Across both studies, dexmedetomidine administered under health care provider supervision resulted in mean reductions of approximately 9.6 points in Positive and Negative Syndrome Scale-Excited Component (PEC) total score at 2 hours following administration, compared with reductions of approximately 4.9 points with placebo.
The company reported that it will announce commercialization plans at a later date.


